Press Releases

Press Releases

Press Releases

June 16, 2022
BRIDGEWATER, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced results of the Company’s Annual General Meeting.  At the Annual General Meeting of the Company held on June 16, 2022 (the AGM ),
May 16, 2022
BRIDGEWATER, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, will present at two upcoming conferences as follows: H.C.
March 9, 2022
BRIDGEWATER, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial
January 19, 2022
-- Fourth Quarter 2021 net sales for UPNEEQ grew by approximately 41% to $3.1 million compared to the third quarter 2021 -- -- Fourth Quarter 2022 net sales for UPNEEQ targeted to range from $20-$25 million -- -- Full national launch into medical aesthetics expected to commence in February 2022 --
Displaying 1 - 10 of 11